DHA+ARA Supplementation in Pregnancy: Mimicking Human Milk Fatty-Acid Profile To Support Fetal Neurodevelopment

The fetal period witnesses the most rapid development of the human brain and nervous system. Maternal nutritional supply during pregnancy directly determines lipid reserves in the fetal brain and retina. Within maternal-infant nutrition, DHA supplementation for expectant mothers is widely accepted. Nevertheless, many pregnant women and industry procurement professionals overlook ARA, which naturally occurs alongside DHA in human milk. ARA is transferred from mother to fetus and constitutes an indispensable long-chain polyunsaturated fatty acid for fetal growth and development. Common questions arise: Is DHA-only supplementation sufficient in pregnancy? Is combined DHA+ARA supplementation necessary? What links exist between DHA+ARA supplementation during gestation and the human-milk-mimicking fatty-acid pattern?

This article provides science-based reading material for pregnant consumers, while delivering professional references for purchasers and brand owners in product selection, channel training and content creation. Drawing on human-milk fatty-acid characteristics, maternal-fetal transfer mechanisms and scientific evidence, it objectively interprets the value, applicable scenarios and safety precautions of DHA+ARA supplementation in pregnancy.

From a physiological perspective, fetuses possess very limited capacity for endogenous synthesis of long-chain polyunsaturated fatty acids. The DHA and ARA required for brain, retinal and organ development are largely supplied by active placental transport from the mother. The fatty-acid profile of human milk serves not only as a nutritional template for postnatal infants but also reflects nutritional demands of intrauterine fetal development. Human-milk DHA-to-ARA ratios range naturally from 1:1 to 1:2, mirroring actual fetal requirements for both fatty acids. The maternal fatty-acid pool acts as the source of DHA and ARA for the fetus. Insufficient maternal ARA reserves may compromise the full assembly of fetal nerve-cell membranes, even with adequate DHA intake.

DHA and ARA perform distinct, non-interchangeable roles in fetal development. DHA accumulates heavily in the fetal hippocampus, cerebral cortex and retinal photoreceptors. It maintains nerve-cell-membrane fluidity, enables efficient nerve-signal transmission, and is critical for fetal cognitive and visual development. ARA likewise exists at high concentrations in fetal brain tissue. It supports neural-cell proliferation and synaptogenesis, participates in placental maturation, fetal skeletal and visceral organ growth-differentiation, and modulates immune responses in both mother and fetus. Simply stated, DHA prioritises signal conduction, whereas ARA drives cell proliferation and tissue construction. Acting synergistically, they sustain rapid intrauterine fetal growth.

Pregnant women possess metabolic pathways converting linoleic acid to ARA and α-linolenic acid to DHA; however, conversion efficiency is constrained by dietary patterns and individual metabolic status. Chinese diets are generally low in omega-3 fatty acids. Some expectant mothers consume insufficient red meat, eggs and other ARA-precursor foods, making ordinary dietary intake inadequate to satisfy combined maternal and fetal demands.

Metabolic competition deserves attention: DHA and ARA share the same desaturase-based metabolic enzyme system. Prolonged high-dose DHA-only supplementation in pregnancy may sequester metabolic enzymes, inhibit linoleic-acid-to-ARA conversion, lower maternal ARA status, and consequently reduce placental ARA delivery to the fetus. This competitive metabolic effect occurs in gestation, albeit less intensely than in infants. Therefore, for pregnant women with inadequate dietary sources, DHA+ARA supplements formulated to mimic human-milk ratios help preserve maternal fatty-acid-pool homeostasis and mitigate metabolic imbalance induced by single-nutrient supplementation.

This does not mean ARA supplementation is mandatory for all pregnant women. Expectant mothers consuming well-balanced diets with regular egg and lean-meat intake obtain sufficient linoleic acid and ARA precursors; DHA/EPA-only supplementation generally meets requirements. Combined DHA+ARA formulations are better suited for three subgroups:

1. Pregnant vegetarians with minimal intake of eggs, dairy and meat;

2. Individuals with monotonous diets and overall low long-chain polyunsaturated fatty-acid intake;

3. Those planning high-dose DHA supplementation and wishing to avoid enzyme-mediated suppression of endogenous ARA synthesis.

Widespread inflammatory concerns should also be clarified. As an omega-6 fatty acid, ARA is subject to online claims that ARA supplementation aggravates gestational inflammation. In reality, ARA supplemented at physiological, human-milk-aligned doses does not trigger chronic inflammation. Inflammatory dysregulation arises primarily from severely imbalanced dietary omega-6-to-omega-3 ratios. Pregnancy itself brings physiological shifts in inflammatory regulation. Women living with autoimmune disorders or active inflammatory conditions should avoid self-administering high-dose ARA supplements and follow guidance from obstetricians or clinical dietitians.

For consumers, core principles for gestational supplementation are summarised below:

1. Follow the Expert Consensus on DHA Supplementation for Chinese Pregnant, Lactating Women and Infants, prioritising DHA intake as the foundation.

2. Avoid standalone high-dose ARA. When selecting combined products, favour ratios referencing human milk: 1:1 ~ 1:1.7.

3. Prioritise whole foods; supplements merely fill dietary gaps and cannot replace regular meals.

4. Pregnant women with underlying medical conditions should consult qualified healthcare practitioners before commencing any nutritional supplements.

From the industry perspective for purchasers and brand developers, product positioning and promotional boundaries must be respected:

1. DHA constitutes the core baseline for prenatal products. DHA+ARA blends target niche populations such as vegetarians and those with inadequate dietary intake. Marketing must not claim "ARA supplementation is compulsory for all pregnant women".

2. Formulate combined products within human-milk-referenced ratio ranges; avoid formulations where ARA greatly exceeds DHA.

3. Deliver channel-focused science communication explaining placental transfer and metabolic-competition mechanisms, while dispelling misconceptions linking ARA intake to inflammation.

4. Comply strictly with advertising regulations. Do not claim products guarantee improved fetal intelligence or vision; restrict messaging to objective descriptions of nutritional supplementation.

5. Enforce rigorous raw-material quality control. Prefer fermented ARA oil and closely monitor oxidation, microbiological and other safety indicators.

In summary, gestational DHA+ARA combinations simulate human-milk fatty-acid patterns. Their core value lies in stabilising the maternal fatty-acid pool, mitigating metabolic competition caused by high-dose DHA monotherapy, and delivering balanced nutrition for fetal neural and tissue development. DHA+ARA is not universally mandatory for pregnant women but represents a valuable nutritional strategy under specific dietary circumstances. Both consumers and industry developers should place whole-food nutrition first, evaluate blended formulations rationally, resist over-hyping and blind adoption, and safeguard prenatal nutritional health through science-informed decisions.

References

[1] Chinese Nutrition Society. Chinese Dietary Reference Intakes (2023 Edition) [M]. Beijing: People's Medical Publishing House, 2023.

[2] Yang Yuexin. Chinese Encyclopedia of Nutrition Science (2nd Edition) [M]. Beijing: People's Medical Publishing House, 2019.

[3] Yin Shian. Human Milk Composition: Forms, Contents, Functions and Detection Methods [M]. Beijing: Chemical Industry Press, 2016.

[4] Expert Group on DHA Supplementation for Chinese Pregnant, Lactating Women and Infants. Expert consensus on DHA supplementation for Chinese pregnant, lactating women and infants [J]. Chinese Journal of Reproductive Health, 2015, 26(2):101-105.

[5] Hadley K B, Ryan A S, Forsyth S, et al. The essentiality of arachidonic acid in infant development [J]. Nutrients, 2016, 8(4):216.

[6] Koletzko B, et al. Current information and Asian perspectives on long-chain polyunsaturated fatty acids in pregnancy, lactation, and infancy [J]. Annals of Nutrition and Metabolism, 2014, 65:49-80.

[7] Calder P C. A systematic review of the effects of increasing arachidonic acid intake on PUFA status, metabolism and health-related outcomes in humans [J]. British Journal of Nutrition, 2019, 121(10):1121-1134.

[8] Szabo A, Boehm G. Placental transfer of long-chain polyunsaturated fatty acids in human pregnancy [J]. Nutrients, 2021, 13(8):2738.